Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC By Ogkologos - April 30, 2026 210 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer March 31, 2026 Today is Random Acts of Kindness Day February 17, 2021 Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam,... September 29, 2022 FDA Approves Capivasertib with Fulvestrant for Breast Cancer November 23, 2023 Load more HOT NEWS Innovative cancer spinouts: 3 new projects get green light EMA Recommends Extension of Therapeutic Indications for Axicabtagene Ciloleucel What to Know About At-Home DNA Tests for Detecting Cancer Risk EMA Recommends Granting a Conditional Marketing Authorisation for Trastuzumab Deruxtecan
